Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its ...

1). Although attention has historically focused on Grb2-mediated recruitment to receptor tyrosine kinases as a means of localizing SOS to the plasma membrane, recent work has revealed increasing ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

Solid Tumor Patient Response in Second ... Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a ...

According to preclinical studies, BP1001-A effectively reduced Grb2 protein expression and enhanced ... to expand beyond its traditional focus on cancer treatments. "These findings address a ...